Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 1
2019 3
2020 1
2021 1
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events.
Les I, Martínez M, Pérez-Francisco I, Cabero M, Teijeira L, Arrazubi V, Torrego N, Campillo-Calatayud A, Elejalde I, Kochan G, Escors D. Les I, et al. Among authors: teijeira l. Cancers (Basel). 2023 Mar 6;15(5):1629. doi: 10.3390/cancers15051629. Cancers (Basel). 2023. PMID: 36900420 Free PMC article. Review.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Hyperprogressive Disease: Main Features and Key Controversies.
Arasanz H, Zuazo M, Bocanegra A, Chocarro L, Blanco E, Martínez M, Morilla I, Fernández G, Teijeira L, Morente P, Echaide M, Castro N, Fernández L, Garnica M, Ramos P, Escors D, Kochan G, Vera R. Arasanz H, et al. Among authors: teijeira l. Int J Mol Sci. 2021 Apr 3;22(7):3736. doi: 10.3390/ijms22073736. Int J Mol Sci. 2021. PMID: 33916696 Free PMC article. Review.
CAR-T Cells for the Treatment of Lung Cancer.
Chocarro L, Arasanz H, Fernández-Rubio L, Blanco E, Echaide M, Bocanegra A, Teijeira L, Garnica M, Morilla I, Martínez-Aguillo M, Piñeiro-Hermida S, Ramos P, Lasarte JJ, Vera R, Kochan G, Escors D. Chocarro L, et al. Among authors: teijeira l. Life (Basel). 2022 Apr 8;12(4):561. doi: 10.3390/life12040561. Life (Basel). 2022. PMID: 35455052 Free PMC article. Review.
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.
Arasanz H, Bocanegra AI, Morilla I, Fernández-Irigoyen J, Martínez-Aguillo M, Teijeira L, Garnica M, Blanco E, Chocarro L, Ausin K, Zuazo M, Fernández-Hinojal G, Echaide M, Fernández-Rubio L, Piñeiro-Hermida S, Ramos P, Mezquita L, Escors D, Vera R, Kochan G. Arasanz H, et al. Among authors: teijeira l. Cancers (Basel). 2022 Aug 9;14(16):3846. doi: 10.3390/cancers14163846. Cancers (Basel). 2022. PMID: 36010840 Free PMC article.
Quality of life of early-stage breast-cancer patients diagnosed with COVID-19 in the first three waves of the epidemic treated in the Spanish region of Navarre.
Arraras JI, Illarramendi JJ, Manterola A, Cruz S, Zarandona U, Ibañez B, Salgado E, Visus I, Barrado M, Teijeira L, Martinez E, Vera R. Arraras JI, et al. Among authors: teijeira l. Psychooncology. 2023 May;32(5):730-740. doi: 10.1002/pon.6118. Epub 2023 Mar 17. Psychooncology. 2023. PMID: 36882856
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D. Zuazo M, et al. Among authors: teijeira l. EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6. EMBO Mol Med. 2019. PMID: 31273938 Free PMC article.
Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study.
Les I, Pérez-Francisco I, Cabero M, Sánchez C, Hidalgo M, Teijeira L, Arrazubi V, Domínguez S, Anaut P, Eguiluz S, Elejalde I, Herrera A, Martínez M. Les I, et al. Among authors: teijeira l. Front Pharmacol. 2022 Jun 1;13:894550. doi: 10.3389/fphar.2022.894550. eCollection 2022. Front Pharmacol. 2022. PMID: 35721217 Free PMC article.
Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective.
Teijeira L, Martínez M, Moreno A, de Elejoste I, Ibáñez-Beroiz B, Arrazubi V, Díaz de Corcuera I, Elejalde I, Campillo-Calatayud A, Les I. Teijeira L, et al. Cancers (Basel). 2023 Dec 28;16(1):151. doi: 10.3390/cancers16010151. Cancers (Basel). 2023. PMID: 38201577 Free PMC article.
14 results